Total : 11 View more »
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today announced the presentation of interim data from its ongoing trial
http://finance.yahoo.com/news/Geron-Presents-Interim-bw-3646802619.html?x=0&.v=1
Filed under: Earnings reports, Technical Analysis<img border="1" hspace="4" alt="" vspace="4" align="right"
http://www.bloggingstocks.com/2009/10/30/geron-corp-spikes-on-narrower-than-forecast-3q-loss/
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief
http://finance.yahoo.com/news/Geron-to-Present-at-LCM-bw-2441048636.html?x=0&.v=1
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN - News) today announced the publication of data showing that oligodendrocyte progenitor cells
http://finance.yahoo.com/news/Geron-Collaborators-Publish-bw-2888040197.html?x=0&.v=1
Total : 3 View more »
Sep 26, 2009 (Wall Street Horizon via COMTEX) --
Geron Corporation (GERN)
Expected next earnings release: Announcement date: 10/29/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Expected next investor conference call information: Conference Call Date: 7/31/2009 Conference Call Time (ET): 11:00 AM Conference Call URL: http://www.geron.com/investors/factsheet/events.aspx
Tags: conference corporate earnings market
Companies: Geron Corp. (GERN)
Sep 25, 2009 (Wall Street Horizon via COMTEX) --
Geron Corporation (GERN)
Expected next earnings release: Announcement date: 10/29/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Expected next investor conference call information: Conference Call Date: 7/31/2009 Conference Call Time (ET): 11:00 AM Conference Call URL: http://www.geron.com/investors/factsheet/events.aspx
Tags: conference corporate earnings market
Companies: Geron Corp. (GERN)
Aug 27, 2009 (SmarTrend(R) News Watch via COMTEX) --
8/27/2009 - Geron Corp. (NASDAQ:GERN) said Thursday that some animals treated with its embryonic stem cell product have developed microscopic spinal cysts. The company is testing GRNOPC1 for spinal cord injury and has been testing it on rats and mice in hopes to begin human clinical trials soon. The FDA is delaying the program due to the new data from the animal studies. Neither the company nor the FDA said how long the review will take. The company said, "A very low frequency of injected animals developed microscopic cysts in the regenerating injury site," and added that the cysts were harmless, were not spreading, and were not connected to increased risk of death or health problems. Geron said as many as half of all spinal cord injury patients develop much larger cysts.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: health market nasdaq securities
Companies: Geron Corp. (GERN)
Total : 17 View more »
Together, they provide valuable advice to help Tercica meet challenges, capture opportunities, and sustain momentum as we plan for our company's future.
Stock quotes, news and charts for Geron Corporation Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,
The following historical press releases contain statements that reflected management's views and estimates of future economic circumstances, industry conditions, company performance and financial results applicable on the dates they were first issued.
BIO CEO & Investor Conference 2007 MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 9, 2007--Geron Corporation (Nasdaq:GERN) will present an update of the company's product development programs at 1:15 p.m. ET on Monday, Feb. 12, 2007, at the BIO CEO & Investor Conference in New York City.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=48648
Total : 71,900 View more »
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV ...
Geron Corporation is a biotechnology company located in Menlo Park, California that specializes in developing and commercialization of products in three specific areas: 1 ...
See the company profile for Geron Corporation (GERN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ...
Get detailed information on Geron Corporation (GERN) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company ...